Adjuvant endocrine therapy for early breast cancer: the story so far. (Q37715990)

22 August 2017

1 reference

title

Adjuvant endocrine therapy for early breast cancer: the story so far. (English)

1 reference

22 August 2017

William J Gradishar

1

1 reference

22 August 2017

publication date

1 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

28

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

433-442

1 reference

Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357901003631098

10.1080/07357901003631098

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference